Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Vanda Pharma Second Quarter Loss Shrinks as Expenses Drop

By Pharmaceutical Processing | July 31, 2013

Vanda Pharmaceuticals Inc. reported a smaller second-quarter loss as a drop in expenses prompted by the completion of some clinical research helped the drug developer.

The Washington, D.C., company, which focuses on developing treatments for center nervous system disorders, lost $3.1 million, or 11 cents per share, in the three-month period that ended June 30. That compares to a loss of $8 million, or 28 cents per share in last year’s quarter.

Revenue slipped slightly to $8.3 million, as royalty payments on sales of the schizophrenia drug Fanapt fell. Swiss drugmaker Novartis AG markets Fanapt.

Analysts surveyed by FactSet expected, on average, a loss of 22 cents per share on $8.4 million in revenue.

Vanda said research and development costs sank 52 percent to about $6 million compared to last year’s quarter, as Vanda completed some studies involving tasimelteon. The company is developing that drug as a potential treatment for non-24-hour disorder, a rare disorder that affects people who are totally blind.

Those patients have difficulty synchronizing their bodies with the 24-hour cycle because they can’t detect light.

The company said the Food and Drug Administration has accepted its application for the drug and classified it for a priority review. The FDA plans to decide on the application by Jan. 31.

Vanda had $103.6 million in cash at the end of the second quarter.

Its shares rose 24 cents, or 2.1 percent, to $11.85 in premarket trading.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE